Other Events. As previously reported in Abbott’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, Abbott is a defendant in numerous lawsuits alleging that preterm infants developed necrotizing enterocolitis (“NEC”) as a result of being administered certain of Abbott’s preterm infant formula products. In a July 2024 Missouri state court trial, a jury awarded a plaintiff (“ Gill ”) $495 mil…

Regulation FD Disclosure. On August 20, 2026, Abbott issued a press release announcing the settlement of a portion of its litigation involving its specialty formulas for preterm infants. A copy of the press release is furnished hereto as Exhibit 99.1 and is incorporated herein by reference. The information contained in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…

Results of Operations and Financial Condition On July 16, 2026, Abbott Laboratories announced its results of operations for the second quarter 2026. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictabl…

The filing is primarily about the approval of a new equity compensation program and the election of a director.

Other Events. As previously disclosed in Abbott’s Annual Reports on Form 10-K for the fiscal years ended December 31, 2024 and December 31, 2025, six shareholder derivative lawsuits have been pending in a consolidated proceeding, In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation , before the United States District Court for the Northern District of Illinois against certain of Abbott’s current and former directors and officers. On April 10, 2026, in connection with tha…

Results of Operations and Financial Condition On April 16, 2026, Abbott Laboratories announced its results of operations for the first quarter 2026. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictabl…

Other Events. On March 23, 2026, Abbott Laboratories, an Illinois corporation (“Abbott”), completed the acquisition of Exact Sciences Corporation, a Delaware corporation (“Exact Sciences”), pursuant to the Agreement and Plan of Merger, dated as of November 19, 2025 (the “Merger Agreement”), by and among Abbott, Exact Sciences and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Abbott (“Merger Sub”). Pursuant to the terms of, and subject to the condit…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information included in

Entry into a Material Definitive Agreement On March 9, 2026, Abbott Laboratories (“Abbott”) completed the public offering and issuance of $20,000,000,000 aggregate principal amount of senior notes, consisting of $1,000,000,000 aggregate principal amount of its Floating Rate Notes due 2029 (the “Floating Rate Notes”), $2,250,000,000 aggregate principal amount of its 3.700% Notes due 2029 (the “2029 Notes”), $2,500,000,000 aggregate principal amount of its 4.000% Notes due 2031 (the “2031 Notes…

Entry into a Material Definitive Agreement On February 23, 2026, Abbott Laboratories (“Abbott”) entered into a pricing agreement (the “Pricing Agreement”), dated February 23, 2026, by and among Abbott, Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, for themselves and as representatives of the several other underwriters named therein (the “Underwriters”), pursuant to which Abbott agreed to issue and sell $20,000,000,000 aggregate principa…

Results of Operations and Financial Condition On January 22, 2026, Abbott Laboratories announced its results of operations for the fourth quarter and full year 2025. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusua…

Director — Nita Ahuja, M.D.: Dr. Nita Ahuja was appointed to the Board of Directors.

Entry into a Material Definitive Agreement. On November 19, 2025, Abbott Laboratories, an Illinois corporation (“Abbott”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Exact Sciences Corporation, a Delaware corporation (“Exact Sciences”), and Badger Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Abbott (“Merger Sub”). The Merger Agreement provides for, among other things, the merger of Merger Sub with and into Exact Sciences (the “Mer…

Results of Operations and Financial Condition On October 15, 2025, Abbott Laboratories announced its results of operations for the third quarter 2025. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredicta…

Results of Operations and Financial Condition On July 17, 2025, Abbott Laboratories announced its results of operations for the second quarter 2025. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictabl…

Executive Vice President, General Counsel and Secretary — Hubert L. Allen: Hubert L. Allen plans to retire after a period of transition.

Results of Operations and Financial Condition On April 16, 2025, Abbott Laboratories announced its results of operations for the first quarter 2025. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictabl…

Results of Operations and Financial Condition On January 22, 2025, Abbott Laboratories announced its results of operations for the fourth quarter and full year 2024. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusua…

The filing is about extending change in control agreements for named executive officers.

Results of Operations and Financial Condition On October 16, 2024, Abbott Laboratories announced its results of operations for the third quarter 2024. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredicta…

Results of Operations and Financial Condition On July 18, 2024, Abbott Laboratories announced its results of operations for the second quarter 2024. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictabl…

Executive Vice President, Finance — Robert E. Funck, Jr.: Robert E. Funck, Jr., plans to retire from the company after 36 years of service.

Results of Operations and Financial Condition On April 17, 2024 , Abbott Laboratories announced its results of operations for the first quarter 2024. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictab…

Termination of a Material Definitive Agreement. In connection with its entry into the Revolving Credit Agreement, on the Effective Date Abbott terminated all commitments outstanding under the Five Year Credit Agreement, dated as of November 12, 2020 (as amended by that certain Amendment No. 1, dated as of May 12, 2023, the “ Existing Credit Agreement ”), among Abbott, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent. There were no outstanding…

by reference. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBOTT LABORATORIES Date: January 29, 2024 By: /s/ Philip P. Boudreau Philip P. Boudreau Senior Vice President, Finance and Chief Financial Officer